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Twelve patients with congenital agammaglobulinemia, 2 of 10 patients with selective 
IgA deficiency, and 4 of 15 patients with common variable immunodeficiency have 
reduced 5’-nucleotidase activity on lymphocyte plasma membranes. In congenital 
agammaglobulinemia and common variable immunodeficiency, enzyme-deficient pa- 
tients have an early onset of immune dysfunction, low levels or an absence of circulating 
B-lymphocytes, and a positive family history of similar immunodeficiency. The enzyme 
deficiency involves peripheral E-rosette-forming lymphocytes, suggesting an abnormal- 
ity of T-lymphocytes in these diseases. No systemic disorder of purine nucleotide degra- 
dation to uric acid is detectable in the enzyme-deficient patients. No direct relationship 
between 5’-nucleotidase activity and in vitro production of IgG is evident, since inhibi- 
tion of the enzyme did not decrease IgG synthesis. At present the data do not allow a 
distinction between two hypotheses to explain the role of 5’-nucleotidase in hypogamma- 
globulinemia, that is, whether 5’-nucleotidase deficiency causes the immune dysfunction 
or is simply a marker for an intrinsic lymphocyte abnormality. However, this enzyme 
deficiency may provide a useful means of classifying disorders of immunoglobulin syn- 
thesis. 
INTRODUCTION 
Purine nucleotide degradation plays an important role in the regulation of the 
human immunologic system. A deficiency of adenosine deaminase occurs with 
severe combined immunodeficiency (1, 2) and purine nucleoside phosphorylase 
deficiency is associated with T-cell dysfunction (3-5) (Fig. 1). Decreased activity 
of 5’-nucleotidase has recently been observed in patients with hypogamma- 
globulinemia of adult onset (6, 7) and in young males with congenital agamma-, 
globulinemia (8). Although an etiologic role for the deficiencies of adenosice, 
deaminase and purine nucleoside phosphorylase in immunodeficiency diseases 
has been suggested by extensive investigations (9, lo), a cause and effect relation- 
ship between lymphocyte 5’-nucleotidase deficiency and hypogammaglobulinemia 
has not been established. 
The purpose of this report is to clarify the relationship between lymphocyte 
5’-nucleotidase deficiency and hypogammaglobulinemia by defining the clinical 
disorders observed in the patients with enzyme deficiency. In our study, every 
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FIG. 1. Purine metabolic pathway. Nucleoside monophosphates (AMP, IMP) are hydrolyzed to 
their respective nucleosides by 5’-nucleotidase (1). Adenosine deaminase (2) converts adenosine to 
inosine. Purine nucleoside phosphorylase (3) catalyzes the reversible phosphorolysis of inosine to 
hypoxanthine, which is then oxidized to xanthine and uric acid by xanthine oxidase (4). Adenine 
(radiolabeled for our in rtvo study) is converted to AMP by adenine phosphoribosyltransferase (5). 
AMP can be converted to ADP and ATP. 
patient with congenital agammaglobulinemia, as defined previously (1 I), has lym- 
phocyte 5’-nucleotidase deficiency. However, patients with other primary immu- 
noglobulin deficiencies also may have this enzyme deficiency. In contrast to 
adenosine deaminase and purine nucleoside phosphorylase deficiencies, no sys- 
temic abnormality of purine nucleotide degradation is observed in subjects with 
5’-nucleotidase deficiency. Preliminary experiments in vitro showed no direct 
relationship between 5’-nucleotidase inhibition and the regulation of immunoglob- 
ulin synthesis. 
MATERIALS AND METHODS 
Materials 
The commercial sources of the reagents used in this study were as follows: 
adenosine, inosine, AMP, ATP, fructose, uricase, xanthine oxidase, and purine 
nucleoside phosphorylase, Sigma Chemical Company, St. Louis, Missouri; 
bovine serum albumin (fraction V, grade B), adenine, hypoxanthine, and xan- 
thine, Calbiochem, San Diego, California; [8-14C]hypoxanthine (50 mCi/mmol), 
[8-14C]inosine (60 mCi/mmol), [8-14C]AMP (50 mCi/mmol), and carrier-free [lz51]- 
iodine, Amersham Company, Arlington Heights, Illinois; [8-14C]adenine (52 
mCi/mmol), New England Nuclear Corp., Boston, Massachusetts; Ficoll-Paque, 
Pharmacia Fine Chemicals, Piscataway, New Jersey; sheep erythrocytes, Micro- 
biological Associates, Walkersville, Maryland; pokeweed mitogen and RPMI- 
1640 with Hepes buffer, Grand Island Biological Company, Grand Island, New 
York; fetal calf serum, Reheis Chemical Company, Chicago, Illinois; carbonyl 
iron, BDH Chemicals Ltd., Dorset, England; adenosine-cy, /?-methylene diphos- 
phate (AOPCP) and rabbit anti-human IgG antiserum, Miles Laboratory, Elk- 
hart, Indiana; fluorescein-conjugated goat F(ab’), anti-human immunoglobulins 
and anti-F-chain antisera, Cappel Laboratories, Cochranville, Pennsylvania; and 
in-line Cathivex filter units (0.22 and 0.45 @f) for the intravenous infusion of 
[8-14C]adenine and D-fructose, Millipore Corp., Bedford, Massachusetts. 
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The immunodeficiency subjects in this study are followed by our Pediatric 
Immunology Service or by Dr. Kenneth Rich, Childrens Hospital, Chicago. 
Twelve patients with a previous diagnosis of congenital agammaglobulinemia 
were subdivided into three groups (Table 1). One child fit the classic definition of 
X-linked agammaglobulinemia with lateral affected maternal male relatives as 
proposed by the WHO Conference on classification of primary immuno- 
deficiencies (12). A second group of seven patients had at least one male sibling 
affected with infantile-onset agammaglobulinemia. A third group of four males 
satisfied all the other criteria for classic X-linked agammaglobulinemia except that 
they had no known relative with similar illness. Other patients with primary im- 
munoglobulin deficiencies were classified as common variable immunodeficiency 
(CVID) or selective IgA deficiency (SIgAD) according to proposed definitions (11, 
12). Control subjects for lymphocyte 5’-nucleotidase assay were healthy adult 
volunteers or age-matched nonimmunodeficient children seen at The University 
of Michigan Pediatric Clinic. 
TABLE 1 






























3.7 M 8 60 0 10 1 
4.0 M 6 1306 0 50 0 
4.8 M 9 2000 0 0 0 
5.2 M ?’ 260* 0 200 2 
5.5 M 18 150* 0 9 2 
5.6 M 6 20 0 0 0 
6.1 M 6 0 0 0 0 
6.3 M 24 2000 0 0 0 
6.5 M 36 22W 0 0 1 
6.5 M 9 4500 0 15 3 
6.9 M 4 20 0 0 0 
7.2 M 6 140 0 30 6” 
7.7 M 3 110* 0 0 1 
8.6 M 32 77 0 0 3d 
9.8 M 16 2200 0 192 6 
10.4 F 6 65 7 10 7” 
10.4 M 360 3135 0 135 11 



















” CAY-congenital agammaglobulinemia (I-classic X-linked; II-familial male affected without 
lateral transmission; III-infantile onset with no known affected relatives); CVID-common variable1 
immunodeficiency; SIgAD-selective IgA deficiency. 
b Postimmunoglobulin therapy. 
c Patient PD was adopted at age 6 years, at which time he already had severe recurrent sinopul-1 
monary disease. 
d Although CVID patients generally have normal numbers of B-cells, a lack of surface Ig-bearing 
lymphocytes in both early and late onset CVID has been reported in as many as 15-20% of the pa- 
tients (e.g., Preud’homme et al., J. Immunol. 114, 481, 1975). 
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Studies of Purine Nucleotide Degradation 
Five patients with congenital agammaglobulinemia, three patients with common 
variable immunodeficiency, and eight gouty adult patients were hospitalized in the 
Clinical Research Center at The University of Michigan. Patients were given a 
purine-free, 70 g protein, weight-maintenance diet. No medications which altered 
uric acid production or excretion were given. On the fourth hospital day, 15 &i 
[8-14C]adenine in 3 pmol adenine was administered intravenously through 0.22~pm 
Cathivex filters to label the intracellular adenine nucleotide pool (total adminis- 
tered dose was 23.2 x lo6 cpm in our liquid scintillation spectrometer). Baseline 
and postinfusion urines were assayed for creatinine content and radioactivity. On 
the seventh hospital day, intravenous fructose (0.5 g/kg) was given over 10 min as 
a provocative test to cause adenine nucleotide pool degradation (13). 
Ecto-5’-Nucleotidase Assay 
Lymphocyte separation was carried out on blood freshly collected in heparin- 
coated tubes (14). Lymphocyte 5’-nucleotidase was measured at pH 7.5 by a 
radiochemical method (8). To test for an interfering effect of adenosine kinase, an 
inhibitor of nucleoside transport, 10 PM dipyradamole, or an inhibitor of 
adenosine kinase, 100 PM 4-amino-5-iodo-7-/3-D-ribofuranosyl-7,14-pyrrole 
(2,3-d) pyrimidine, was added to our assay system (15, 16). The addition of either 
of these compounds did not increase nucleoside formation. These data suggest 
that adenosine kinase does not significantly influence our 5’-nucleotidase assay. 
Substrate competition assays were performed for lymphocytes from normal and 
5’-nucleotidase-deficient subjects using 25 PM [S-14C]AMP and 1 m&I purine or 
pyrimidine nucleoside monophosphates. Substrate competition for lymphocyte 
5’-nucleotidase was estimated by the inhibition of enzyme activity. 
Confluent monolayers of cultured diploid fibroblasts were assayed for 5’- 
nucleotidase in 35 x lo-mm culture plates. After growth in Eagle’s minimum 
essential medium with 10% fetal calf serum, monolayers were washed three times 
with 5 ml of 150 n&I NaCl in 10 mM Tris-HCl, pH 7.5. Activity of 5’-nucleotidase 
was assayed with a 4-ml reaction mixture containing 50 mM Tris-HCl, pH 7.5, 4 
mM MgCl,, 150 nG4 NaCl, and 0.2 mM AMP at 37°C for 7.5 min. One hundred 
microliters of supernatant was removed at time 0 and 7.5 min and assayed for 
inorganic phosphate content (17). Fibroblasts of each monolayer were counted 
following trypsinization. This assay was linear with cell number and time to 
20 min. 
Cell Preparation 
Separation of gradient-purified mononuclear cells into rosette-forming and 
non-rosette-forming populations was carried out using sheep erythrocytes (18). 
The fresh mononuclear cells, suspended to 2 x lo6 cells/ml in Hanks’ balanced 
salt solution without calcium and magnesium, were mixed with equal volumes of 
0.5% washed sheep erythrocytes and 15% heat-inactivated, absorbed fetal calf 
serum in siliconized glass tubes and centrifuged at 200g for 5 min. The mononu- 
clear cell-sheep erythrocyte suspension was incubated for 10 hr at 4°C. The cells 
were then gently resuspended by rotation and placed on a Ficoll-Paque gradient 
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for separation into rosette-forming and non-rosette-forming cells. Monocyte de- 
pletion of either the mixed peripheral mononuclear cells or the non-rosette- 
forming fraction was performed using carbonyl iron (19). Monocyte contamination 
of mononuclear cell preparations was determined by a nonspecific esterase 
stain (20). 
In Vitro Zmmunoglobulin Synthesis 
To study the differentiation of lymphocytes to immunoglobulin secreting plasma 
cells, peripheral blood lymphocytes were adjusted to a concentration of 1 x lo6 
cells/ml in RPMI-1640 with Hepes buffer supplemented with penicillin, strep- 
tomycin, glutamine, and heat-inactivated fetal calf serum. Two-milliliter aliquots 
were dispensed into loosely capped 10 x 75mm plastic tubes to which were added 
100 ~1 of pokeweed mitogen and 0 to 100 fl AOPCP. All cultures were prepared 
in duplicate and incubated for 7 days at 37°C in humidified chambers containing 
5% carbon dioxide in air. At the end of the incubation period, the culture tubes 
were spun and the supernatant fluids were aspirated and assayed for IgG concen- 
tration. The IgG secreted into the medium was measured by a tube-binding 
radioimmunoassay with rabbit anti-human IgG antiserum and lz51-labeled human 
IgG (21). 
Other Assays 
Erythrocytes were obtained by spinning heparinized blood at 1OOOg for 5 min at 
4°C. The plasma was removed and frozen at -20°C. The erythrocytes were 
washed twice with cold 150 rnJ4 sodium chloride and frozen at -70°C for sub- 
sequent enzyme assay. 
Adenosine deaminase, purine nucleoside phosphorylase, and adenine and 
hypoxanthine -guanine phosphoribosyltransferases were assayed using 
radiochemical methods (22-24). Serum urate concentration and urinary uric acid, 
oxypurines, and inosine were quantitated by enzymatic spectrophotometric 
methods (25-27). The inosine assay measured both inosine and 2’-deoxyinosine. 
Creatinine was measured by a modification of the technique of Folin and Wu (28). 
Protein was estimated by the method of Lowry et a/. (29), with crystalline bovine 
serum albumin as a standard. 
RESULTS 
Enzyme Deficiency and Clinical Features 
Plasma membrane 5’-nucleotidase values are listed in Fig. 2. Normal subjects 
showed a wide range of lymphocyte 5’-nucleotidase activity, from 12.3 to 41.1 
nmol/hr/lO” lymphocytes (mean value of 21.1). Enzyme levels were relatively 
constant for a given individual on multiple analyses. All 12 patients with congeni- 
tal agammaglobulinemia showed a reduction in lymphocyte 5’-nucleotidase activ- 
ity, with values ranging from 3.7 to 7.7 nanomollhr/106 lymphocytes. Four of 15 
patients with common variable immunodeficiency and 2 of 10 with selective IgA 
deficiency also had reduced 5’-nucleotidase levels. All patients had normal values 
for erythrocyte adenosine deaminase and purine nucleoside phosphorylase. Lym- 
phocyte 5’-nucleotidase was measured in six mothers of eight patients with con- 














2-4 6-11 IO-12 14-16 M-20 22-24 26-28 
Lymphocyte Ecto 5’-N 
(nmol/hour/lOe cells) 
FIG. 2. Distribution of lymphocyte 5’-nucleotidase (5,-N) in primary hypogammaglobulinemia. Low 
enzyme activity is present in 12 of 12 patients with congenital agammaglobulinemia, 4 of I5 with 
common variable hypogammaglobulinemia, and 2 of 10 patients with selective IgA deficiency. 
genital agammaglobulinemia. They had a mean value of 20.2 (range 13.0-26.8) 
nanomol/hr/lO” cells, compared to the mean value for 12 normal females of 25.8 
(range 14.5-40.2). 
The clinical and immunologic features of these patients are listed in Tables 1 and 
2. No single clinical variable used in classification uniquely correlated with lym- 
phocyte 5’-nucleotidase deficiency. In general, patients diagnosed as either con- 
genital agammaglobulinemia or common variable immunodeficiency with low 5’- 
nucleotidase levels had lower percentages of circulating B-cells and an earlier 
onset of immune deticiency. No difference in the clinical or immunologic features 
was evident for the patients with selective IgA deficiency having normal or de& 
cient lymphocyte 5’-nucleotidase. 
The existence of circulating or lymphocyte membrane-bound inhibitors of 5’- 
nucleotidase was investigated with mixing experiments. Plasma from either nor- 
mal or 5’-nucleotidase-deficient subjects had no inhibitory effect on 5’-nucleo- 
tidase activity in assays of either normal or enzyme-deficient lymphocytes. When 
normal and enzyme-deficient peripheral blood lymphocytes were mixed at a 1 to 1 
ratio, the resulting 5’-nucleotidase activity was the expected median value be- 
tween the normal and the deficient enzyme activity. Therefore, there was no 
evidence for the existence of an inhibitor. 
Additional studies did not provide evidence for a structural alteration of the 
deficient enzyme. In peripheral blood lymphocytes from normal and enzyme- 
deficient subjects, 5’-nucleotidase had similar values for pH optimum, degree of 
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5’-AMP (8). The substrate specificity for the puke nucleotides was similar in the 
normal and enzyme-deficient lymphocytes. Lymphocyte 5’-nucleotidase prefer- 
entially degraded substrate ribonucleoside 5’-monophosphates with the following 
relative activities: AMP = GMP > IMP > CMP > XMP. 
An effort was made to distinguish whether the enzyme deficiency in congenital 
agammaglobulinemia might result simply from the absence of B-cells. Peripheral 
blood mononuclear cells from 10 normal and 5 agammaglobulinemic subjects were 
isolated on Ficoll-Paque gradients and then fractionated further into E-rosette- 
forming and non-E-rosette-forming subpopulations. The E-rosette-forming and 
non-E-rosette-forming cells had comparable 5’-nucleotidase activities; their val- 
ues were similar to those found in mixed peripheral lymphocytes from both the 
normal subjects and the patients with congenital agammaglobulinemia (Table 3, 
Study A). It is noteworthy that the E-rosette-forming cells had evidence of the 
enzyme deficiency. 
In order to determine whether monocyte contamination of the peripheral blood 
lymphocytes might account for the enzyme deficiency, monocyte depletion was 
performed on the peripheral blood mononuclear cells from nine normal subjects 
and eight patients with congenital agammaglobulinemia using carbonyl iron inges- 
tion (Table 3, Study B). Normal postgradient cells contained 5 to 14% monocytes 
as determined by nonspecific esterase staining. Postgradient mononuclear cells 
from subjects with congenital agammaglobulinemia had 10 to 26% monocytes. 
Monocyte-depleted preparations showed 3 to 7% monocytes for the normal sub- 
jects and 4 to 10% for the agammaglobulinemic patients. Although a modest 
increase in 5’-nucleotidase activity was found, the enzyme deficiency persisted. 
The alteration of mononuclear cell subpopulations did not account for the ob- 
served enzyme deficiency. 
TABLE 3 
S’-NUCLEOTIDASE ACTIVITY AND LYMPHOCYTE POPULATIONS 
Congenital 
Normal agammaglobulinemia 
(nmol/hr/lO” cells) (nmol/hr/lO” cells) 
Study A (N = 10) (N = 5) 
Fresh peripheral 
mononuclear cells 19.3” 5.9 
(12.8-27.5) (3.3-9.0) 
E-rosette-forming cells 22.5 7.1 
(12.8-34.1) (3.3-11.8) 
Non-E-rosette-forming cells 28.1 6.6 
(12.0-43.2) (2.8-8.4) 
Study B (N = 9) (N = 8) 
Peripheral mononuclear cells 
Premonocyte depletion 17.6 6.4 
(12.6-24.8) (2.2-M) 
Postmonocyte depletion 24.8 7.6 
(15.2-40.2) (5.5-11.0) 
’ Values represent mean activity for each cell population with range of values in parentheses. 
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TABLE 4 
5'-NUCLEOTIDASE IN CULTUREDDIPLOID FIBROBLASTS 
5’-Nucleotidase (pmol/hr/lO” cells) 
Subject Normal Congenital agammaglobulinemia 
1 36.0 12.0 
2 16.3 9.3 
3 13.4 7.9 
4 10.0 7.1 
Mean value 18.9 9.1 
In order to discern whether 5’-nucleotidase deficiency was unique to lympho- 
cytes or whether the deficiency occurred in other tissues, cultured diploid fibro- 
blasts were grown from skin biopsies from four normal subjects and four boys 
with congenital agammaglobulinemia. The activity of 5’-nucleotidase was mea- 
sured in the intact fibroblast monolayers through all stages of cell growth. High 
levels of enzyme activity were present in the early logarithmic phase of cell 
growth. Plasma membrane 5’-nudleotidase activity diminished at the time of con- 
fluent cell growth and became stable during the late confluent stage of growth. 
During late confluent cell growth (day 16 postpassage) in fibroblast cell lines, 
5’-nucleotidase was 900-fold more active than in lymphocytes (Table 4). The over- 
lapping enzyme activity in fibroblasts from the two patient populations did not 
demonstrate a definitive difference. 
Purine Nucleotide Degradation 
Plasma urate levels and urinary uric acid excretion were normal in patients with 
lymphocyte 5’-nucleotidase deficiency. Purine nucleotide degradation was mea- 
sured directly by the excretion of radioactively labeled purine compounds in the 
urine after labeling the adenine nucleotide pool with tracer doses of [8-14C]adenine 
(27). The cumulative radioactivity excretion in the urine during the first 5 day? 
ranged from 5.5 to 13% in six subjects with lymphocyte 5’-nucleotidase deficiency 
and was 11.8 and 10.8% in two young males with common variable immunodeti- 
ciency and normal 5’-nucleotidase (Fig. 3). Thus there was no evidence of a 
systemic reduction in the degradation of nucleotides in patients with 5’-nucleo- 
tidase deficiency using this measure. 
The infusion of D-fructose, a sensitive provocative test, was used to examine 
purine nucleotide degradation in vivo (4, 13). Six patients with 5’-nucleotidase 
deficiency and two patients with common variable immunodeficiency and normal 
enzyme activity were first injected with [8-14C]adenine and then given intravenous 
fructose 4 days later. Urinary radioactivity increased rapidly during the first hour 
following fructose infusion in both groups of patients (Fig. 4). In six patients with 
lymphocyte 5’-nucleotidase deficiency, total urinary purine (the sum of uric acid, 
xanthine, hypoxanthine, and inosine) increased from baseline levels of 2.4 + 0.8 
millimol/g creatinine to 9.1 & 4.0 millimol/g creatinine in the first hour following 
fructose administration. The mean increase of 6.7 millimol/g creatinine was com- 
parable to the elevated purine excretion of 7.5 & 4.2 millimol/g creatinine ob- 
served in eight adult control subjects. The two subjects with common variable 
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I 2 3 4 5 
Days 
FIG. 3. Cumulative urinary radioactivity excretion following intravenous [8-‘YZ]adenine. At day 0, 
15 PCi of [8-‘C]adenine (total infusion = 23.2 x 10” cpm in our liquid scintillation spectrometer) is 
administered to subjects and urinary radioactivity excretion is measured. The slope of radioactivity 
excretion in six patients with lymphocyte 5’-nucleotidase deficiency (5’-N-) is similar to that seen in 
two age-matched patients with hypogammaglobulinemia and normal lymphocyte 5’nucIeotidase 
(5’-N+). 
immune deficiency and normal 5’-nucleotidase levels had increased purine excre- 
tion of 8.4 and 10.9 millimol/g creatinine in the first hour following fructose infu- 
sion. Serum urate concentration increased similarly following fructose infusion in 
all three groups of patients. Thus, the in viva isotope and fructose studies showed 
no consistent evidence for a systemic deficiency of 5’-nucleotidase in subjects 
with decreased lymphocyte 5’-nucleotidase. 
Urinary Radioactivity 
0 I 2 3 0 I 2 3 
Hours Hours 
FIG. 4. Effect of intravenous o-fructose on purine excretion in hypogammaglobulinemia. Fructose 
(0.5 g/kg) is administered intravenously starting at time 0 for 10 to 15 min. Urine is collected for 1 hr 
prior to and 3 hr following fructose infusion. Total urinary purine excretion (left) includes the sum of 
uric acid, hypoxanthine, xanthine, and inosine. Baseline purine excretion for 5’-Nm patients is 2.39 ? 
0.81 mmol/g creatinine and for 5’-N+ patients is 3.00 and 2.79 mmol/g creatinine. The increase in 
urinary radioactivity (right) following fructose infusion reflects the degradation of adenine nucleotides 
previously labeled with [8-“C]adenine. Baseline radioactivity excretion for 5’-N- patients is 0.065 -t 
0.026% of the administered dose and for 5’-N+ patients is 0.051 and 0.062%. Patients with nucleotidase 
deficiency (5’-N-) or with normal enzyme activity (5,-N+) respond similarly to fructose. 
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TABLE 5 









IgG secretion” (ng/lO” lymphocytes) 
Subject A Subject B 
162 2 57 497 + 121 
170 2 20 495 A 97 
180 ” 40 727 k 187 
171 It 33 687 ” 237 
151 * 39 790 t 262 
” Values express the mean + standard deviation of two experiments performed on each subject in 
duplicate. 
Zmmunoglobulin Synthesis and 5’-Nucleotidase Inhibition 
To assess whether 5’-nucleotidase activity regulates immunoglobulin synthesis, 
IgG secretion by activated lymphocytes was assayed with and without a potent 
inhibitor of 5’-nucleotidase (Table 5). Although the average secretion of IgG ap- 
pears to be stimulated by the higher concentrations of AOPCP, there were no 
statistical differences among the values for each subject by Student’s t test. Thus, 
there was no simple relationship between IgG secretion in vitro and 5’-nucleo- 
tidase activity. 
DISCUSSION 
A reduction of lymphocyte 5’-nucleotidase occurs in patients with congenital 
agammaglobulinemia (Fig. 2) (8), other forms of hypogammaglobulinemia (Fig. 2) 
(68), acute and chronic lymphatic leukemia (30-32), and acute infectious mono- 
nucleosis (31). In general, the patients in our study with congenital agamma- 
globulinemia or common variable immunodeficiency and lymphocyte 5’-nucleo- 
tidase deficiency have an earlier clinical onset of immune dysfunction, lower 
numbers of circulating B-lymphocytes, and a greater propensity for familial occur- 
rence (Tables 1 and 2) than do patients with similar diagnoses and normal lympho- 
cyte 5’-nucleotidase activity. 
In contrast to deficiencies of adenosine deaminase and purine nucleoside phos- 
phorylase, there is no detectable alteration of systemic purine metabolism in 
patients with 5’nucleotidase deficiency and no tissue other than peripheral cir- 
culating mononuclear cells exhibits the enzyme deficiency. Our patients with 
iymphocyte 5’-nucleotidase deficiency have no alteration of purine nucleotide 
degradation as shown by the normal values for plasma urate concentration, uri- 
nary uric acid excretion, and urinary radioactivity excretion and the response to 
o-fructose infusion. 
An etiologic relationship between lymphocyte 5’-nucleotidase deficiency and 
abnormally low immunoglobulin synthesis has not been established. In the im- 
mune deficiency states associated with adenosine deaminase deficiency or purine 
nucleoside phosphorylase deficiency, an accumulation of purine nucleosides and 
deoxynucleosides leads to increased concentrations of tissue purine deoxy- 
nucleoside triphosphates (9,33-37). These latter compounds are toxic to lympho- 
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cytes. An accumulation of deoxynucleoside triphosphates does not occur in lym- 
phocytes and erythrocytes from patients with 5’-nucleotidase deficiency (38). 
Therefore, it appears unlikely that there is a shared mechanism of immune toxicity 
occurring in 5’-nucleotidase deficiency and the other forms of purinogenic im- 
munodeficiency. However, our recent observations suggest that 5’-nucleotidase 
activity may be a plasma membrane marker for the mature T-lymphocyte, since 
human thymocytes have very low levels of this enzyme (39). Thus, 5’-nucleo- 
tidase deficiency may be the consequence of altered lymphocyte subpopulations 
rather than a cause of the disease itself. 
The role of lymphocyte 5’-nucleotidase in cellular metabolism is not clear. This 
enzyme degrades nucleoside 5’-monophosphates to their nucleoside derivatives in 
the following reaction: nucleoside monophosphate + H,O + nucleoside + Pi. It is 
known that highly charged nucleoside monophosphate derivatives are not trans- 
ported across cell membranes in usual circumstances. Nucleosides released by the 
5’-nucleotidase reaction, however, are freely transported into the cell, and recent 
studies suggest that 5’-nucleotidase may actually function as an adenosine trans- 
locase (40). 
Whether 5’-nucleotidase deficiency leads to hypogammaglobulinemia, is a 
marker for patients that share a common maturational block of lymphocyte devel- 
opment, or connotes an alteration of lymphocyte subpopulations is not currently 
known. Further clinical observations are necessary to distinguish among these 
possibilities. However, the measurement of lymphocyte 5’-nucleotidase may pro- 
vide both a rational basis for classifying the primary hypogammaglobulinemias 
and a useful clinical diagnostic technique. 
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